XCancer

Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer

Description:

1. Based on the treatment response and prognosis of mHSPC patients with novel endocrine therapy, a PSMA PET whole-body tumor burden classification was constructed to guide treatment and evaluate prognosis. 2. Based on the treatment response and prognosis of mHSPC patients with novel endocrine therapy, a multivariable model will be constructed using quantitative parameters of PSMA PET/CT imaging, pre-treatment gene status, PSA, GS/ISUP and other clinical pathological parameters to further achieve accurate patient classification, guide treatment, and evaluate prognosis.

Sponsor:

Peking University First Hospital

Phase:

N/A

Contacts:

Hongwei Sun, Dr (CONTACT)

lxhxixi@163.com

0086-10-83575252

Xuhe Liao, Dr (CONTACT)

liaoxuhe@bjmu.edu.cn

0086-10-83575252

Government Study Link:

NCT06387238 - Click here to see study on

ClinicalTrials.gov

PSMA-11

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: HBED-CC
Inclusion
  • Patient age\>18 years old.
  • Patients with KPS score ≥ 50 (ECOG/WHO equivalent).
  • * Prostate cancer patients confirmed to have metastasis by PSMA PET/CT before new endocrine therapy.
  • Those who have not undergone androgen deprivation treatment in the past, or have currently received androgen deprivation treatment for no more than 120 days without progress, or have received androgen deprivation treatment in the past (treatment time less than 24 months and no progress within 12 months after completion).
Exclusion
  • Patients who cannot understand and voluntarily participate in this trial, donnot sign an informed consent form, and aren't able to cooperate independently in completing the examination.